Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05416073
Other study ID # pain during TACE-HAIC
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date June 22, 2022
Est. completion date April 30, 2023

Study information

Verified date June 2022
Source The Second Affiliated Hospital of Chongqing Medical University
Contact Duan Guang you, MD
Phone 18323376014
Email duangy@hospital.cqmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Previous studies have confirmed that limb pain caused by oxaliplatin chemotherapy is related to spinal cord central sensitization - induced hyperalgesia through oxaliplatin activating spinal cord NMDA receptor(N-methyl-D-aspartic acid receptor). The investigators speculate that this may be the same as the mechanism of severe abdominal pain caused by HAIC(Hepatic Artery Infusion Chemotherapy) during oxaliplatin infusion. The analgesic effect of Esketamine is mainly related to its inhibition of NMDA receptor in spinal cord. Therefore, this study hypothesized that Esketamine can inhibit the sensitization of spinal cord center by inhibiting NMDA receptor, so as to alleviate severe abdominal pain during HAIC perfusion, and reduce abdominal pain caused by ischemia and inflammation by TACE(transcatheter arterial chemoembolization) by improving organ perfusion and anti-inflammatory effect, Therefore, it is expected that Esketamine can better alleviate acute severe abdominal pain caused by TACE-HAIC (transcatheter arterial chemoembolization combined with Hepatic Artery Infusion Chemotherapy )treatment than sufentanil, decrease the dosage of opioids, and reduce the incidence and degree of chronic abdominal pain after treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date April 30, 2023
Est. primary completion date April 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Participate in this study and sign informed consent - Voluntarily receive postoperative intravenous controlled analgesia - Patients receiving TACE-HAIC treatment - HCC (hepatocellular carcinoma)patients with primary liver cancer BCLC(Barcelona Clinic Liver Cancer) stage B and C, liver function A - Age 18 to 80 Exclusion Criteria: - Patients who were unable to cooperate or refused to participate in the trial - Pregnant women - Patients with sensory abnormalities such as diabetes neuropathy - Patients with or having a history of serious mental disorders - Patients with poorly controlled or untreated hypertension (arterial hypertension, resting systolic / diastolic blood pressure more than 180/100mg) - Patients with unstable angina pectoris or myocardial infarction within 6 months or congestive heart failure - Patients with intracranial hypertension or glaucoma - Patients with hyperthyroidism without treatment or insufficient treatment - Patients with severe respiratory dysfunction - Allergy or existing contraindication to chemotherapeutic drugs, opioids or ketamine drugs - Can not follow with the study procedure

Study Design


Intervention

Drug:
Esketamine
PCIA formula:100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)< 4; If NRS = 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
Sufentanil
PCIA formula:100ml analgesic solution was prepared by adding 2 µ g/kg sufentanil and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)< 4; If NRS = 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.

Locations

Country Name City State
China The Second Affiliated Hospital, Chongqing Medical University Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
The Second Affiliated Hospital of Chongqing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Ramsay Sedation score at 1 hour after HAIC treatment Ramsay Sedation score is assessed by:
Grade 1 (soberness- the patient is anxious, uneasy or irritable)? Grade 2 (soberness- the patient is cooperative, has good orientation or is quiet)? Grade 3 (soberness- the patient only responds to commands)? Grade 4 (sleep-the patient responds quickly to light tapping between eyebrows or strong sound stimulation)? Grade 5 (sleep-the patient responds slowly to light tapping between the eyebrows or strong sound stimulation) and Grade 6 (sleep-the patient has no response to light tapping between eyebrows or strong sound stimulation). Grade 1 indicates no sedation ; Grade 2 and 3 indicate good sedation ; Grade 4 to 6 indicate poor sedation.
From the beginning of HAIC treatment to 1 hour after HAIC treatment
Other Ramsay Sedation score at 2 hours after HAIC treatment Ramsay Sedation score is assessed by:
Grade 1 (soberness- the patient is anxious, uneasy or irritable)? Grade 2 (soberness- the patient is cooperative, has good orientation or is quiet)? Grade 3 (soberness- the patient only responds to commands)? Grade 4 (sleep-the patient responds quickly to light tapping between eyebrows or strong sound stimulation)? Grade 5 (sleep-the patient responds slowly to light tapping between the eyebrows or strong sound stimulation) and Grade 6 (sleep-the patient has no response to light tapping between eyebrows or strong sound stimulation). Grade 1 indicates no sedation ; Grade 2 and 3 indicate good sedation ; Grade 4 to 6 indicate poor sedation.
From 1 hour to 2 hours after HAIC treatment
Other Ramsay Sedation score at 3 hours after HAIC treatment Ramsay Sedation score is assessed by:
Grade 1 (soberness- the patient is anxious, uneasy or irritable)? Grade 2 (soberness- the patient is cooperative, has good orientation or is quiet)? Grade 3 (soberness- the patient only responds to commands)? Grade 4 (sleep-the patient responds quickly to light tapping between eyebrows or strong sound stimulation)? Grade 5 (sleep-the patient responds slowly to light tapping between the eyebrows or strong sound stimulation) and Grade 6 (sleep-the patient has no response to light tapping between eyebrows or strong sound stimulation). Grade 1 indicates no sedation ; Grade 2 and 3 indicate good sedation ; Grade 4 to 6 indicate poor sedation.
From 2 hours to 3 hours after HAIC treatment
Other Ramsay Sedation score at 8 hours after HAIC treatment Ramsay Sedation score is assessed by:
Grade 1 (soberness- the patient is anxious, uneasy or irritable)? Grade 2 (soberness- the patient is cooperative, has good orientation or is quiet)? Grade 3 (soberness- the patient only responds to commands)? Grade 4 (sleep-the patient responds quickly to light tapping between eyebrows or strong sound stimulation)? Grade 5 (sleep-the patient responds slowly to light tapping between the eyebrows or strong sound stimulation) and Grade 6 (sleep-the patient has no response to light tapping between eyebrows or strong sound stimulation). Grade 1 indicates no sedation ; Grade 2 and 3 indicate good sedation ; Grade 4 to 6 indicate poor sedation.
From 7 hours to 8 hours after HAIC treatment
Other The quality of sleep on the fist day after HAIC treatment The Richards-Campbell Sleep Questionnaire (RCSQ) is assessed by the quality of patients' sleep quality.0~25 points indicate poor sleep quality;76~100 points indicate good sleep quality (0-100, 0 represents the worst sleep quality; 100 represents the best sleep quality ;higher scores mean a better outcome) From the ending of HAIC treatment to 1 day after HAIC treatment
Other The quality of sleep on the second day after HAIC treatment The Richards-Campbell Sleep Questionnaire (RCSQ) is assessed by the quality of patients' sleep quality.0~25 points indicate poor sleep quality;76~100 points indicate good sleep quality (0-100, 0 represents the worst sleep quality; 100 represents the best sleep quality ;higher scores mean a better outcome) From 1 day to 2 days after HAIC treatment
Other The quality of sleep on the third day after HAIC treatment The Richards-Campbell Sleep Questionnaire (RCSQ) is assessed by the quality of patients' sleep quality.0~25 points indicate poor sleep quality;76~100 points indicate good sleep quality (0-100, 0 represents the worst sleep quality; 100 represents the best sleep quality ;higher scores mean a better outcome) From 2 days to 3 days after HAIC treatment
Other Adverse reaction Adverse reaction is recorded according to follow-up visits after HAIC treatment From the beginning of HAIC treatment to 72 hours after HAIC treatment
Other Degree of satisfaction Degree of satisfaction is assessed by patient using numerical rating scale (0-10, 0 represents unsatisfactory; 10 represents complete satisfaction;higher scores mean a better outcome) From the beginning of HAIC treatment to 24 hours after HAIC treatment
Primary Maximum pain intensity in the first 3 hours of HAIC treatment Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome) From the beginning of HAIC treatment to 3 hours after HAIC treatment
Primary Pain intensity at 1 hour after HAIC treatment Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome) From the beginning of HAIC treatment to 1 hour after HAIC treatment
Primary Pain intensity at 2 hours after HAIC treatment Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome) From 1 hour to 2 hours after HAIC treatment
Primary Pain intensity at 3 hours after HAIC treatment Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome) From 2 hours to 3 hours after HAIC treatment
Secondary Numbers of analgesic pump compressions When the patients felt pain, the patient controlled analgesia pump can be pressed once From the beginning of HAIC treatment to 48 hours after HAIC treatment
Secondary Analgesic consumption Analgesic consumption is assessed by the total amount of pain remedy with dolantin when the analgesic effect is poor after pressing analgesic pump for 3 times or more From the beginning of HAIC treatment to 48 hours after HAIC treatment
Secondary Pain intensity at 8 hours after HAIC treatment Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome) From 7 hours to 8 hours after HAIC treatment
Secondary Pain intensity at 16 hours after HAIC treatment Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome) From 15 hours to 16 hours after HAIC treatment
Secondary Pain intensity at 24 hours after HAIC treatment Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome) From 23 hours to 24 hours after HAIC treatment
Secondary Pain intensity at 32 hours after HAIC treatment Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome) From 31 hours to 32 hours after HAIC treatment
Secondary Pain intensity at 40 hours after HAIC treatment Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome) From 39 hours to 40 hours after HAIC treatment
Secondary Pain intensity at 48 hours after HAIC treatment Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome) From 47 hours to 48 hours after HAIC treatment
Secondary Pain intensity on the seventh days after HAIC treatment Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome) From 7 days to 8 days after HAIC treatment
Secondary Pain intensity On the 14th day after HAIC treatment Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome) From 13 days to 14 days after HAIC treatment
Secondary Pain intensity on the 21st after HAIC treatment Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome) From 20 days to 21 days after HAIC treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Terminated NCT04356352 - Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain Phase 2/Phase 3
Completed NCT04748367 - Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care N/A
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04466111 - Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05868122 - A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Phase 3
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT03273114 - Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain N/A
Enrolling by invitation NCT06087432 - Is PNF Application Effective on Temporomandibular Dysfunction N/A
Completed NCT05508594 - Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 Phase 2/Phase 3
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Active, not recruiting NCT03472300 - Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
Completed NCT03678168 - A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries N/A
Completed NCT03286543 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System N/A
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT02913027 - Can We Improve the Comfort of Pelvic Exams? N/A
Terminated NCT02181387 - Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor? Phase 4
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Active, not recruiting NCT03613155 - Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care